2型糖尿病基础胰岛素控制不佳者换用每周一次胰岛素icodec与每日一次甘精胰岛素U100的2期随机对照试验
本项多中心、开放标签、治疗达标2期试验将基础胰岛素日剂量10-50单位、HbA1c 7.0-10.0%的2型糖尿病患者按1:1:1随机分为icodec负荷剂量组、icodec无负荷剂量组和每日一次甘精胰岛素U100组治疗16周。主要终点第15-16周葡萄糖目标范围内时间(TIR)在三组分别为72.9%、66.0%和65.0%,icodec负荷剂量组较甘精胰岛素U100组显著提高7.9个百分点(95%CI 1.8-13.9)。各组不良事件和低血糖发生率相似,换用每周一次icodec耐受良好且血糖控制有效。
要点
- 换用icodec时采用负荷剂量可显著提高TIR,优于每日甘精胰岛素U100。
- icodec负荷剂量组TIR较甘精胰岛素U100组高7.9个百分点(95%CI 1.8-13.9)。
- 各组不良事件和低血糖发生率相似,未增加低血糖风险。
核心结论
- 从每日基础胰岛素换用每周一次icodec耐受良好并提供有效血糖控制。
- 换用icodec时使用负荷剂量较每日一次甘精胰岛素U100显著提高第15-16周TIR,且不增加低血糖风险。
研究设计与样本
- 多中心、开放标签、治疗达标2期随机对照试验,按1:1:1随机分组治疗16周。
- 纳入基础胰岛素日剂量10-50单位、HbA1c 7.0-10.0%(53.0-85.8 mmol/mol)的2型糖尿病患者。
- 三组分别为icodec初始100%负荷剂量(仅首次剂量加倍)、icodec无负荷剂量和每日一次甘精胰岛素U100。
- 主要终点为第15-16周持续葡萄糖监测测量的TIR(3.9-10.0 mmol/L [70-180 mg/dL])百分比。
主要发现
- 第15-16周估算平均TIR:icodec负荷剂量组72.9%(n=54),icodec无负荷剂量组66.0%(n=50),甘精胰岛素U100组65.0%(n=50)。
- icodec负荷剂量组较甘精胰岛素U100组TIR高7.9个百分点(95%CI 1.8-13.9),差异有统计学意义。
- 平均HbA1c从基线7.9%(62.8 mmol/mol)降至icodec负荷剂量组7.1%(54.4 mmol/mol),icodec无负荷剂量组和甘精胰岛素U100组均为7.4%(57.6 mmol/mol)。
- 不良事件和低血糖发作的发生率与发生率在三组间相当。
临床怎么用
- 对每日基础胰岛素控制不佳的2型糖尿病患者,可考虑换用每周一次icodec。
- 换用icodec时采用首次剂量加倍的负荷剂量策略有助于提高TIR且不增加低血糖风险。
局限性
- 为2期随机对照试验,样本量较小。
- 开放标签设计。
- 治疗期仅16周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to icodec versus once-daily insulin glargine 100 units/mL (IGlar U100) in people with type 2 diabetes receiving daily basal insulin and one or more oral glucose-lowering medications. RESEARCH DESIGN AND METHODS: This multicenter, open-label, treat-to-target phase 2 trial randomized (1:1:1) eligible basal insulin-treated (total daily dose 10-50 units) people with type 2 diabetes (HbA1c 7.0-10.0% [53.0-85.8 mmol/mol]) to icodec with an initial 100% loading dose (in which only the first dose was doubled [icodec LD]), icodec with no loading dose (icodec NLD), or IGlar U100 for 16 weeks. Primary end point was percent time in range (TIR; 3.9-10.0 mmol/L [70-180 mg/dL]) during weeks 15 and 16, measured using continuous glucose monitoring. Key secondary end points included HbA1c, adverse events (AEs), and hypoglycemia. RESULTS: Estimated mean TIR during weeks 15 and 16 was 72.9% (icodec LD; n = 54), 66.0% (icodec NLD; n = 50), and 65.0% (IGlar U100; n = 50), with a statistically significant difference favoring icodec LD versus IGlar U100 (7.9%-points [95% CI 1.8-13.9]). Mean HbA1c reduced from 7.9% (62.8 mmol/mol) at baseline to 7.1% (54.4 mmol/mol icodec LD) and 7.4% (57.6 mmol/mol icodec NLD and IGlar U100); incidences and rates of AEs and hypoglycemic episodes were comparable. CONCLUSIONS: Switching from daily basal insulin to once-weekly icodec was well tolerated and provided effective glycemic control. Loading dose use when switching to once-weekly icodec significantly increased percent TIR during weeks 15 and 16 versus once-daily IGlar U100, without increasing hypoglycemia risk.
引用
- Bajaj HS, Bergenstal RM, Christoffersen A, et al. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Diabetes Care. 2021. PMID: 33875485. doi:10.2337/dc20-2877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。